Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes

BACKGROUND: The reshaping of the immune landscape by nivolumab (NIVO) and ipilimumab (IPI) and its relation to patient outcomes is not well described. METHODS: We used high-parameter flow cytometry and a computational platform, CytoBrute, to define immunophenotypes of up to 15 markers to assess peri...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Woods, David M., Laino, Andressa S., Winters, Aidan, Alexandre, Jason, Freeman, Daniel, Rao, Vinay, Adavani, Santi S., Weber, Jeffery S., Chattopadhyay, Pratip K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2020
Aiheet:
Clinical Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7308045/
https://ncbi.nlm.nih.gov/pubmed/32369447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.137066
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia